BACKGROUND: Thromboelastography (TEG) is used to diagnose perturbations in clot formation and lysis that are characteristic of acute traumatic coagulopathy. With novel functional fibrinogen (FF) TEG, fibrin- and platelet-based contributions to clot formation can be elucidated to tailor resuscitation and thromboprophylaxis. We sought to describe the longitudinal contributions of fibrinogen and platelets to clot strength after injury, hypothesizing that low levels of FF and a low contribution of fibrinogen to clot strength on admission would be associated with coagulopathy, increased transfusion requirements, and worse outcomes. METHODS: A total of 603 longitudinal plasma samples were prospectively collected from 251 critically injured patients at a single Level 1 trauma center from 0 hour to 120 hours. TEG maximal amplitude (MA), FF MA, FF levels, von Clauss fibrinogen, and standard coagulation measures were performed in parallel. Percentage contributions of FF (%MA(FF)) and platelets (%MA(platelets)) were calculated as each MA divided by overall kaolin TEG MA. RESULTS: Coagulopathic patients (international normalized ratio ≥ 1.3) had significantly lower admission %MA(FF) than noncoagulopathic patients (24.7% vs. 31.2%, p < 0.05). Patients requiring plasma transfusion had a significantly lower admission %MA(FF) (26.6% vs. 30.6%, p < 0.05). Higher admission %MA(FF) was predictive of reduced mortality (hazard ratio, 0.815, p < 0.001). %MA(platelets) was higher than %MA(FF) at all time points, decreased over time, and stabilized at 72 hours (69.4% at 0 hour, 56.2% at 72 hours). In contrast, %MA(FF) increased over time and stabilized at 72 hours (30.6% at 0 hour, 43.8% at 72 hours). CONCLUSION: FF TEG affords differentiation of fibrin- versus platelet-based clot dynamics. Coagulopathy and plasma transfusion were associated with a lower %MA(FF). Despite this importance of fibrinogen, platelets had a greater contribution to clot strength at all time points after injury. This suggests that attention to these relative contributions should guide resuscitation and thromboprophylaxis and that antiplatelet therapy may be of underrecognized importance to thromboprophylaxis after trauma. LEVEL OF EVIDENCE: Prognostic study, level III.
BACKGROUND: Thromboelastography (TEG) is used to diagnose perturbations in clot formation and lysis that are characteristic of acute traumatic coagulopathy. With novel functional fibrinogen (FF) TEG, fibrin- and platelet-based contributions to clot formation can be elucidated to tailor resuscitation and thromboprophylaxis. We sought to describe the longitudinal contributions of fibrinogen and platelets to clot strength after injury, hypothesizing that low levels of FF and a low contribution of fibrinogen to clot strength on admission would be associated with coagulopathy, increased transfusion requirements, and worse outcomes. METHODS: A total of 603 longitudinal plasma samples were prospectively collected from 251 critically injured patients at a single Level 1 trauma center from 0 hour to 120 hours. TEG maximal amplitude (MA), FF MA, FF levels, von Claussfibrinogen, and standard coagulation measures were performed in parallel. Percentage contributions of FF (%MA(FF)) and platelets (%MA(platelets)) were calculated as each MA divided by overall kaolin TEG MA. RESULTS: Coagulopathic patients (international normalized ratio ≥ 1.3) had significantly lower admission %MA(FF) than noncoagulopathic patients (24.7% vs. 31.2%, p < 0.05). Patients requiring plasma transfusion had a significantly lower admission %MA(FF) (26.6% vs. 30.6%, p < 0.05). Higher admission %MA(FF) was predictive of reduced mortality (hazard ratio, 0.815, p < 0.001). %MA(platelets) was higher than %MA(FF) at all time points, decreased over time, and stabilized at 72 hours (69.4% at 0 hour, 56.2% at 72 hours). In contrast, %MA(FF) increased over time and stabilized at 72 hours (30.6% at 0 hour, 43.8% at 72 hours). CONCLUSION:FF TEG affords differentiation of fibrin- versus platelet-based clot dynamics. Coagulopathy and plasma transfusion were associated with a lower %MA(FF). Despite this importance of fibrinogen, platelets had a greater contribution to clot strength at all time points after injury. This suggests that attention to these relative contributions should guide resuscitation and thromboprophylaxis and that antiplatelet therapy may be of underrecognized importance to thromboprophylaxis after trauma. LEVEL OF EVIDENCE: Prognostic study, level III.
Authors: Mitchell Jay Cohen; Mariah Call; Mary Nelson; Carolyn S Calfee; Charles T Esmon; Karim Brohi; Jean Francois Pittet Journal: Ann Surg Date: 2012-02 Impact factor: 12.969
Authors: Max V Wohlauer; Ernest E Moore; Scott Thomas; Angela Sauaia; Ed Evans; Jeffrey Harr; Christopher C Silliman; Victoria Ploplis; Francis J Castellino; Mark Walsh Journal: J Am Coll Surg Date: 2012-05 Impact factor: 6.113
Authors: Matthew E Kutcher; Brittney J Redick; Ryan C McCreery; Ian M Crane; Molly D Greenberg; Leslie M Cachola; Mary F Nelson; Mitchell Jay Cohen Journal: J Trauma Acute Care Surg Date: 2012-07 Impact factor: 3.313
Authors: Herbert Schöchl; Ulrike Nienaber; Marc Maegele; Gerald Hochleitner; Florian Primavesi; Beatrice Steitz; Christian Arndt; Alexander Hanke; Wolfgang Voelckel; Cristina Solomon Journal: Crit Care Date: 2011-03-04 Impact factor: 9.097
Authors: Victor Jeger; Sandra Willi; Tun Liu; Daniel D Yeh; Marc De Moya; Heinz Zimmermann; Aristomenis K Exadaktylos Journal: ScientificWorldJournal Date: 2012-04-01
Authors: Nathan J White; Jason C Newton; Erika J Martin; Bassem M Mohammed; Daniel Contaifer; Jessica L Bostic; Gretchen M Brophy; Bruce D Spiess; Anthony E Pusateri; Kevin R Ward; Donald F Brophy Journal: Shock Date: 2015-08 Impact factor: 3.454
Authors: Geoffrey R Nunns; Ernest E Moore; Michael P Chapman; Hunter B Moore; Gregory R Stettler; Erik Peltz; Clay C Burlew; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Am J Surg Date: 2017-09-18 Impact factor: 2.565
Authors: Emily F Midura; Peter L Jernigan; Joshua W Kuethe; Lou Ann Friend; Rosalie Veile; Amy T Makley; Charles C Caldwell; Michael D Goodman Journal: J Surg Res Date: 2015-03-05 Impact factor: 2.192
Authors: Belinda H McCully; Christopher R Connelly; Kelly A Fair; John B Holcomb; Erin E Fox; Charles E Wade; Eileen M Bulger; Martin A Schreiber Journal: J Am Coll Surg Date: 2017-03-16 Impact factor: 6.113
Authors: Jason Samuels; Peter J Lawson; Alexander P Morton; Hunter B Moore; Kirk C Hansen; Angela Sauaia; Jonathan A Schoen Journal: Surg Obes Relat Dis Date: 2019-04-10 Impact factor: 4.734
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: Peter J Lawson; Hunter B Moore; Ernest E Moore; Mark E Gerich; Gregory R Stettler; Anirban Banerjee; Richard D Schulick; Trevor L Nydam Journal: J Surg Res Date: 2018-06-08 Impact factor: 2.192